Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
University of Colorado Cancer Center
Aurora, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Colorado Cancer Center (4)
2021
2020
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Lung Cancer, Vol. 150, pp. 90-96
-
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Journal of Clinical Oncology
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654